SignalXSignalX

AMICUS THERAPEUTICS, INC. (FOLD) 8-K Current Report: March 3, 2026

Filed: March 3, 2026
Health Care
Pharmaceutical Preparations
AMICUS THERAPEUTICS, INC. Overview

AMICUS THERAPEUTICS, INC. (FOLD) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 5.07: Submission of Matters to a Vote of Security Holders

AMICUS THERAPEUTICS, INC. 8-K Mar 3, 2026 Event Analysis

Item 5.07 · Submission of Matters to a Vote of Security Holders

  • • Stockholder approval secured: 234.6M shares (99.9% of votes cast) approved BioMarin acquisition of Amicus, clearing key merger condition
  • • FTC early termination granted Feb 11, 2026 — U.S. antitrust clearance already obtained
  • • Remaining hurdles: European and Japanese regulatory approvals plus other customary closing conditions
  • • Deal expected to close Q2 2026; merger agreement dated Dec 19, 2025 with BioMarin as acquirer via wholly owned subsidiary

Get deeper insights on AMICUS THERAPEUTICS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.